Imunon (DB:CBO) - Aandelenkoers, Nieuws & Analyse

CBO Overzicht aandelen

Imunon, Inc., een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën en vaccins voor de behandeling van kanker en infectieziekten. Meer informatie

CBO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 22% per jaar dalen.

Heeft minder dan 1 jaar cash runway

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

+ 3 meer risico's

Imunon, Inc. Concurrenten

Medigene

XTRA:MDG1

€20.6m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

4SC

DB:VSC

€51.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Imunon
Historische aandelenkoersen
Huidige aandelenkoers	US$0.76
52 Week Hoogtepunt	US$3.70
52 Week Laag	US$0.44
Bèta	2.13
11 maand verandering	-9.52%
3 maanden verandering	-25.49%
1 Jaar Verandering	-9.52%
33 jaar verandering	-92.21%
5 jaar verandering	-96.13%
Verandering sinds IPO	-99.93%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CBO	DE Biotechs	DE Markt
7D	21.6%	0.8%	0.8%
1Y	-9.5%	-18.3%	8.6%

Rendement versus industrie: CBO overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -18.3 % opleverde.

Rendement versus markt: CBO presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is CBO's price volatile compared to industry and market?
CBO volatility
CBO Average Weekly Movement	10.4%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van CBO is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CBO is het afgelopen jaar gedaald van 35% naar 10%, maar is nog steeds hoger dan 75% van de German -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1982	33	Stacy Lindborg	imunon.com

Imunon, Inc., een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën en vaccins voor de behandeling van kanker en infectieziekten. Het belangrijkste klinische programma van het bedrijf, IMNN-001, is een op DNA gebaseerde immuuntherapie voor de plaatselijke behandeling van eierstokkanker die zich in fase II van de klinische ontwikkeling bevindt. De producten in preklinische fase omvatten IMNN-101, een COVID-19 boostervaccin; IMNN-102 voor de behandeling van het Lassa-virus; en IMNN-201, een Trp2 tumorgeassocieerd antigeen kankervaccin in melanoom.

Imunon, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Imunon zich tot de beurswaarde?
CBO fundamentele statistieken
Marktkapitalisatie	€11.25m
Inkomsten(TTM)	-€18.57m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.6x

Koers/Winstverhouding

Is CBO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CBO resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$1.67m
Brutowinst	-US$1.67m
Overige uitgaven	US$17.78m
Inkomsten	-US$19.45m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.34
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CBO op de lange termijn?

Bekijk historische prestaties en vergelijking

CBO Overzicht aandelen

Risicoanalyse

Imunon, Inc. Concurrenten

XTRA:MDG1

€20.6m

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

DB:VSC

€51.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Recent updates

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020)

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)